Table 4.
Subgroup analysis of included randomized controlled trials for the effect of CoQ10 supplementation on HbA1c.
| Group | No. of trials (participates) | WMD (95% CI) , % | Pdifferencea | I2, % | Pheterogeneityb | Pc for between subgroup heterogeneity |
|---|---|---|---|---|---|---|
| Overall | 31 (1505) | −0.12(−0.23, −0.01) | 0.04 | 49.10 | <0.001 | |
| Study design | ||||||
| Parallel | 30 (1459) | −0.13(−0.25, −0.01) | 0.04 | 50.64 | <0.001 | 0.40 |
| Crossover | 1 (46) | 0.00(−0.28, 0.28) | 1.00 | - | - | |
| Duration (week) | ||||||
| <12 | 6 (305) | −0.06(−0.28, 0.16) | 0.59 | 43.10 | 0.12 | 0.56 |
| ≥12 | 25 (1200) | −0.14(−0.27, 0.00) | 0.05 | 51.10 | <0.001 | |
| CoQ10 dosage | ||||||
| <200 mg/day | 12 (584) | −0.47(−0.83, −0.12) | <0.001 | 69.17 | 0.00 | 0.05 |
| ≥200 mg/day and <300 mg/day | 13 (666) | −0.03(−0.15, 0.10) | 0.70 | 27.85 | 0.16 | |
| ≥300 mg/day | 6 (255) | −0.01(−0.14, 0.12) | 0.92 | 0.00 | 0.54 | |
| Control group | ||||||
| Placebo | 29 (1434) | −0.12 (−0.23, 0.00) | 0.05 | 51.39 | <0.001 | 0.82 |
| Other | 2 (71) | −0.18 (−0.72, 0.36) | 0.52 | 14.87 | 0.29 | |
| Quality of study | ||||||
| High | 11 (397) | −0.18 (−0.41, 0.04) | 0.12 | 23.84 | 0.22 | 0.53 |
| Low | 20 (1108) | −0.10 (−0.23, 0.03) | 0.15 | 57.92 | <0.001 | |
| Received industry funding? | ||||||
| Yes | 13 (603) | 0.02(−0.07, 0.11) | 0.69 | 0.00 | 0.99 | <0.001 |
| No | 18 (902) | −0.28(−0.48, −0.08) | <0.001 | 66.30 | <0.001 |
Abbreviations: WMD, weighted mean difference; CI, confidence interval; CoQ10, coenzyme Q10.
a
Dersimonian–Laird random effect model was used to calculate the effect size and P-value.
b
Cochrane Q test was used to detect the heterogeneity between studies.
c
Cochrane Q test was used to detect the subgroup heterogeneity.